Analysts have been eager to weigh in on the Healthcare sector with new ratings on Neurocrine (NBIX – Research Report) and Ultragenyx Pharmaceutical (RARE – Research Report).
Neurocrine (NBIX)
Needham analyst Ami Fadia maintained a Hold rating on Neurocrine today. The company’s shares closed last Monday at $133.66.
According to TipRanks.com, Fadia is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Neurocrine with a $152.14 average price target.
See today’s best-performing stocks on TipRanks >>
Ultragenyx Pharmaceutical (RARE)
Stifel Nicolaus analyst Dae Gon Ha maintained a Buy rating on Ultragenyx Pharmaceutical today and set a price target of $124.00. The company’s shares closed last Monday at $43.69.
According to TipRanks.com, Ha is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ultragenyx Pharmaceutical with a $91.80 average price target, which is an 112.4% upside from current levels. In a report released yesterday, RBC Capital also initiated coverage with a Buy rating on the stock with a $77.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NBIX:
- Neurocrine, Sentia Medical Sciences extend CRF research collaboration
- Voyager announces selection of development candidate for GBA1 Program
- Neurocrine initiates Phase 1 study of NBI-1065890
- Neurocrine price target raised to $158 from $148 at JPMorgan
- Spruce Biosciences downgraded to Market Perform from Outperform at Leerink
